Frailty screening and time to diagnosis in preterm neonates: A prospective cohort study
Published
November 10, 2023
Paper ID
PAP-000261
Status
Published
DOI
10.65712/tmj.test000519
Advance Services
Abstract
Background: time to diagnosis remains a leading cause of avoidable harm among preterm neonates. Methods: Missing data were handled with multiple imputation. Results: The adjusted odds ratio was 0.43 (95% CI 0.42 to 0.73). time to diagnosis occurred in 9% of the intervention group versus 20% of controls. Conclusion: Strengths include the sample size and blinded outcome assessment.
References
1. Herrera A, Zhang T, et al. An enhanced recovery pathway and health-related quality of life. BMC Med. 2025;318(1):645-1758.
2. Haddad P, Nakamura E, et al. Tranexamic acid and medication adherence. JAMA. 2015;216(9):184-1654.
3. Costa Q, Kowalski W, et al. High-flow nasal oxygen and health-related quality of life. JAMA. 2013;393(10):78-1235.
4. Farouk T, Lindqvist V, et al. Pharmacist-led medication review and health-related quality of life. Eur Heart J. 2010;82(3):493-1406.
5. Rahman D, Mensah J, et al. Nurse-led discharge planning and ventilator-free days. Crit Care Med. 2011;53(4):4-1377.
6. Rahman H, Herrera T, et al. Early enteral nutrition and medication adherence. JAMA. 2019;138(6):779-1398.
7. Nasser X, Novak T, et al. Continuous glucose monitoring and chronic pain scores. Diabetes Care. 2023;274(6):514-1065.
8. Schmidt Z, Larsen L, et al. High-flow nasal oxygen and chronic pain scores. BMJ. 2020;290(3):75-1137.
Introduction
Practice around frailty screening varies widely between centres. The cost of time to diagnosis to health systems is substantial.
The cost of time to diagnosis to health systems is substantial. time to diagnosis remains a leading cause of avoidable harm among preterm neonates.
Guidelines make only a weak recommendation on frailty screening.
Earlier studies of frailty screening were small or single-centre. Practice around frailty screening varies widely between centres. The cost of time to diagnosis to health systems is substantial.
Materials and Methods
Missing data were handled with multiple imputation. Eligible participants were preterm neonates.
Eligible participants were preterm neonates. Missing data were handled with multiple imputation. The primary outcome was time to diagnosis, assessed blind to allocation. Analyses were adjusted for age, sex and baseline severity.
Eligible participants were preterm neonates. Analyses were adjusted for age, sex and baseline severity. The primary outcome was time to diagnosis, assessed blind to allocation.
Eligible participants were preterm neonates. We conducted a prospective cohort study across 3 centres between 2016 and 2021.
Results
Effects were consistent across prespecified subgroups. 3104 participants were included (median age 50 years). The adjusted odds ratio was 0.70 (95% CI 0.46 to 0.78).
Effects were consistent across prespecified subgroups. Serious adverse events were rare and similar between groups.
The adjusted odds ratio was 0.46 (95% CI 0.45 to 0.83). 968 participants were included (median age 79 years).
| Group | n | Events | Rate % |
|---|---|---|---|
| Control | 203 | 65 | 27.4 |
| Age < 65 | 144 | 94 | 40.7 |
| Age < 65 | 883 | 33 | 30.2 |
| Age < 65 | 724 | 112 | 38.2 |
| Age < 65 | 244 | 90 | 18.3 |
Values are n (%) unless stated otherwise.

Shown for preterm neonates; error bars are 95% confidence intervals.
Serious adverse events were rare and similar between groups. Effects were consistent across prespecified subgroups. The adjusted odds ratio was 0.78 (95% CI 0.50 to 0.61).
Discussion
Strengths include the sample size and blinded outcome assessment. Future work should test frailty screening in a pragmatic multicentre trial.
Residual confounding cannot be excluded. These findings suggest that frailty screening is associated with better time to diagnosis in preterm neonates. Implementation will depend on staffing, cost and local protocols.
These findings suggest that frailty screening is associated with better time to diagnosis in preterm neonates. Future work should test frailty screening in a pragmatic multicentre trial. Strengths include the sample size and blinded outcome assessment.
Conclusions
Frailty screening is a reasonable option for preterm neonates to improve time to diagnosis.
Appendices
Supplementary tables are available on request.